Niraula Apeksha, Baral Nirmal, Lamsal Madhab, Bataju Mahima, Thapa Saroj
Department of Clinical Biochemistry, Institute of Medicine, Tribhuvan University Teaching Hospital, Maharajgunj, Nepal.
Department of Biochemistry, B.P. Koirala Institute of Health Sciences, Dharan, Nepal.
SAGE Open Med. 2022 Jul 5;10:20503121221108613. doi: 10.1177/20503121221108613. eCollection 2022.
The global pandemic due to coronavirus disease 2019 (COVID-19) has posed an overall threat to modern medicine. The course of the disease is uncertain with varying forms of presentation that cannot be managed solely with clinical skills and vigor. Since its inception, laboratory medicine forms a backbone for the proper diagnosis, treatment, monitoring, and prediction of the severity of the disease. Clinical biochemistry, an integral component of laboratory medicine, has been an unsung hero in the disease prognosis and severity assessment in COVID-19. This review attempts to highlight the biomarkers which have shown a significant role and can be used in the identification, stratification, and prediction of disease severity in COVID-19 patients. It also highlights the basis of the use of these biomarkers in the disease course and their implications.
2019年冠状病毒病（COVID-19）引发的全球大流行对现代医学构成了全面威胁。该疾病的病程不确定，表现形式多样，仅靠临床技能和活力无法应对。自疫情开始以来，检验医学一直是疾病正确诊断、治疗、监测及严重程度预测的支柱。临床生物化学作为检验医学的一个重要组成部分，在COVID-19疾病预后和严重程度评估中一直默默发挥着作用。本综述旨在强调那些已显示出重要作用、可用于识别、分层和预测COVID-19患者疾病严重程度的生物标志物。它还强调了这些生物标志物在疾病进程中的应用依据及其意义。
